← Back to Patent Explorer
US4513002A Expired / Lapsed US ⏱️ 0.0 years remaining

Cycloheptene derivatives

Assignee: F Hoffmann La Roche AG
•
Filing: 1981-12-14
•
Granted: 1985-04-23
•
Expires: 2001-12-14
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract 1-[2-(4,5,10,11-Tetrahydro-1H-dibenzo[a,d]cyclohepten-5-yl)ethyl]pyrro lidine of the formula <IMAGE> I and its pharmaceutically acceptable acid addition salts, prepared through various intermediates, are described. The compounds have valuable histamine-H1 antagonistic properties and are suitable for the control or prevention of allergic reactions, such as, urticaria, hay fever, anaphylaxis and over-sensitivity to medicaments.

Inventors

  • 👤 Werner Aschwanden
  • 👤 Quirico Branca
  • 👤 Emilio Kyburz
  • 👤 Rudolf Pfister

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-30 22:37
CPC Classifications
C; C07; C07D; C07D207/00; C07D207/02; C07D207/04; C07D295/00; C07D295/02; C07D295/027; C07D295/03; A; A61; A61P; A61P37/00; A61P37/08; C07C; C07C2603/00; C07C2603/02; C07C2603/04; C07C2603/30; C07C2603/32

Claims Analysis

Total Claims: 3
Claim 1
Independent Claim 30 words
A method of controlling or preventing allergic reactions which comprises administering to a host requiring such treatment an effective amount of 1-[2-(4,5,10,11-tetrahydro-1H-dibenzo[a,d]cyclohepten-5-yl)ethyl]pyrrolidine or a pharmaceutically acceptable acid addition salt thereof.
Claim 2
Independent Claim 30 words
A method of controlling or preventing allergic reactions which comprises administering to a host requiring such treatment an effective amount of 1-[2-(4,5,10,11-tetrahydro-1H-dibenzo[a,d]cyclohepten-5-yl)ethyl]pyrrolidine or a pharmaceutically acceptable acid addition salt thereof.
Claim 3
Dependent Claim 31 words
A method in accordance with claim 1, wherein 1-[2-(4,5,10,11-tetrahydro-1H-dibenzo[a,d]cyclohepten-5-yl)ethyl]pyrrolidine or a pharmaceutically acceptable acid addition salt thereof is administered orally in a daily dosage of about 10 mg to 150 mg.

References Cited (Backward Citations)

US3409640A Cited
GB1017696A Cited
US4136116A Cited
US4127717A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1988-04-22 1988-10-22 1989-04-23 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1992-04-22 1992-10-22 1993-04-23 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1996-04-22 1996-10-22 1997-04-23 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag